Viridian Therapeutics, Inc./DE Basic Shares Outstanding (Weighted Average)
Viridian Therapeutics, Inc./DE (VRDN) reported Basic Shares Outstanding (Weighted Average) of 66.42 million shares for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2024-11-12
- Viridian Therapeutics, Inc./DE weighted average number of shares outstanding, basic for the quarter ending 2024-09-30 was 66.42M shares, a 52.15% increase year-over-year.
- Viridian Therapeutics, Inc./DE weighted average number of shares outstanding, basic for the quarter ending 2024-06-30 was 63.85M shares, a 47.63% increase year-over-year.
- Viridian Therapeutics, Inc./DE weighted average number of shares outstanding, basic for the quarter ending 2024-03-31 was 61.10M shares, a 44.64% increase year-over-year.
- Viridian Therapeutics, Inc./DE weighted average number of shares outstanding, basic for the quarter ending 2023-12-31 was 49.85M shares, a 22.68% increase year-over-year.
- Viridian Therapeutics, Inc./DE weighted average number of shares outstanding, basic for fiscal 2023 was 44.76M shares, a 39.48% increase from fiscal 2022.
- Viridian Therapeutics, Inc./DE weighted average number of shares outstanding, basic for fiscal 2022 was 32.09M shares, a 169.22% increase from fiscal 2021.
- Viridian Therapeutics, Inc./DE weighted average number of shares outstanding, basic for fiscal 2021 was 11.92M shares, a 235.07% increase from fiscal 2020.
- Viridian Therapeutics, Inc./DE weighted average number of shares outstanding, basic for fiscal 2020 was 3.56M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2024-09-30 | 66.42M shares 10-Q · filed 2024-11-12 | 65.14M shares derived: average of 2 quarters · filed 2024-11-12 | 63.80M shares 10-Q · filed 2024-11-12 | 60.31M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 63.85M shares 10-Q · filed 2024-08-08 | 62.48M shares 10-Q · filed 2024-08-08 | 58.27M shares derived: average of 3 quarters · filed 2024-08-08 | 54.61M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2024-03-31 | 61.10M shares 10-Q · filed 2024-05-08 | 55.47M shares derived: average of 2 quarters · filed 2024-05-08 | 51.53M shares derived: average of 3 quarters · filed 2024-11-12 | 49.46M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2023-12-31 | 49.85M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 46.75M shares derived: average of 2 quarters · filed 2024-11-12 | 45.59M shares derived: average of 3 quarters · filed 2024-11-12 | 44.76M shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 43.65M shares 10-Q · filed 2024-11-12 | 43.45M shares derived: average of 2 quarters · filed 2024-11-12 | 43.06M shares 10-Q · filed 2024-11-12 | 42.45M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | 43.25M shares 10-Q · filed 2024-08-08 | 42.75M shares 10-Q · filed 2024-08-08 | 42.04M shares derived: average of 3 quarters · filed 2024-08-08 | 39.97M shares derived: average of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 42.24M shares 10-Q · filed 2024-05-08 | 41.44M shares derived: average of 2 quarters · filed 2024-05-08 | 38.87M shares derived: average of 3 quarters · filed 2024-05-08 | 36.10M shares derived: average of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | 40.63M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 37.19M shares derived: average of 2 quarters · filed 2024-02-27 | 34.05M shares derived: average of 3 quarters · filed 2024-02-27 | 32.09M shares 10-K · filed 2024-02-27 |
| 2022-09-30 | 33.74M shares 10-Q · filed 2023-11-13 | 30.75M shares derived: average of 2 quarters · filed 2023-11-13 | 29.24M shares 10-Q · filed 2023-11-13 | 27.46M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | 27.76M shares 10-Q · filed 2023-08-08 | 26.95M shares 10-Q · filed 2023-08-08 | 25.37M shares derived: average of 3 quarters · filed 2024-02-27 | 21.82M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | 26.13M shares 10-Q · filed 2023-05-10 | 24.17M shares derived: average of 2 quarters · filed 2024-02-27 | 19.84M shares derived: average of 3 quarters · filed 2024-02-27 | 16.91M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | 22.21M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 16.70M shares derived: average of 2 quarters · filed 2024-02-27 | 13.83M shares derived: average of 3 quarters · filed 2024-02-27 | 11.92M shares 10-K · filed 2024-02-27 |
| 2021-09-30 | 11.18M shares 10-Q · filed 2022-11-14 | 9.65M shares derived: average of 2 quarters · filed 2022-11-14 | 8.49M shares 10-Q · filed 2022-11-14 | 7.39M shares derived: average of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | 8.11M shares 10-Q · filed 2022-08-15 | 7.23M shares 10-Q · filed 2022-08-15 | 6.13M shares derived: average of 3 quarters · filed 2022-08-15 | 5.52M shares derived: average of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | 6.34M shares 10-Q · filed 2022-05-13 | 5.14M shares derived: average of 2 quarters · filed 2022-05-13 | 4.66M shares derived: average of 3 quarters · filed 2022-05-13 | 4.38M shares derived: average of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | 3.94M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | 3.83M shares derived: average of 2 quarters · filed 2022-03-11 | 3.73M shares derived: average of 3 quarters · filed 2022-03-11 | 3.56M shares 10-K · filed 2022-03-11 |
| 2020-09-30 | 3.72M shares 10-Q · filed 2021-11-05 | 3.63M shares derived: average of 2 quarters · filed 2021-11-05 | 3.43M shares 10-Q · filed 2021-11-05 | |
| 2020-06-30 | 3.54M shares 10-Q · filed 2021-08-12 | 3.29M shares 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |